| Autor: |
Finotti M; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy.; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA., Romano M; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Grossi U; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Dalla Bona E; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Pelizzo P; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Piccino M; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Scopelliti M; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy., Zanatta P; Department of Anesthesiology and Critical Care, Treviso Regional Hospital AULSS 2 Marca Trevigiana, 31100 Treviso, Italy., Zanus G; Hepatobiliary and General Surgery Unit, Regional Hospital Treviso, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche (DISCOG), University of Padua, 35128 Padua, Italy. |
| Abstrakt: |
Liver transplantation is the preferred treatment for end-stage liver disease. Emerging evidence suggests a potential role for liver transplantation in treating liver tumors such as colorectal liver metastases and cholangiocarcinoma. However, due to a limited donor pool, the use of marginal grafts from donation after circulatory death (DCD) donors is increasing to meet demand. Machine perfusion is crucial in this context for improving graft acceptance rates and reducing ischemia-reperfusion injury. Few studies have evaluated the role of machine perfusion in the context of transplant oncology. Perfusion machines can be utilized in situ (normothermic regional perfusion-NRP) or ex situ (hypothermic and normothermic machine perfusion), either in combination or as a complement to conventional in situ cold flush and static cold storage. The objective of this analysis is to provide an up-to-date overview of perfusion machines and their function in donation after circulatory death with particular attention to their current and likely potential effects on transplant oncology. A literature review comparing standard cold storage to machine perfusion methods showed that, so far, there is no evidence that these devices can reduce the tumor recurrence rate. However, some evidence suggests that these innovative perfusion techniques can improve graft function, reduce ischemia-reperfusion injury, and, based on this mechanism, may lead to future improvements in cancer recurrence. |
